Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/23/2021 | $12.00 → $7.00 | Buy | Canaccord Genuity |
| 12/1/2021 | $16.00 → $7.00 | Overweight | Barclays |
| 11/30/2021 | $9.00 → $4.50 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $15.00 → $4.00 | Buy → Hold | Jefferies |
| 10/29/2021 | $14.00 | Buy | BTIG |
| 8/2/2021 | $15.00 | Buy | Jefferies |
| 7/19/2021 | $62.00 → $43.00 | Buy | Canaccord Genuity |
| 7/16/2021 | $45.00 → $9.00 | Equal-Weight | Morgan Stanley |
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
4 - Sigilon Therapeutics, Inc. (0001821323) (Issuer)
Canaccord Genuity reiterated coverage of Sigilon Therapeutics with a rating of Buy and set a new price target of $7.00 from $12.00 previously
Barclays reiterated coverage of Sigilon Therapeutics with a rating of Overweight and set a new price target of $7.00 from $16.00 previously
Morgan Stanley reiterated coverage of Sigilon Therapeutics with a rating of Equal-Weight and set a new price target of $4.50 from $9.00 previously